Adalvo is pleased to announce positive progress in the registration process for Mirabegron prolonged-release tablets in European markets.
This product has been developed in collaboration with one of our strategic partners, based on the reference brand, Betmiga prolonged-release tablets. It is indicated in the treatment of urgency, increased micturition frequency and urgency incontinence.
The brand sold approximately $3130 Mn globally in 2022, with a Global 3Y CAGR of 5%, according to IQVIA.
The introduction of Mirabegron into Adalvo's portfolio reflects the company's ongoing commitment to expanding its offerings and meeting the evolving needs of healthcare providers and patients alike.
Partner up now!
At Adalvo, we believe in the power of collaboration to drive success. As the pioneer in bringing Apremilast to European markets, we are committed to optimising market penetration effectively. If you're seeking a strategic partner to propel your business forward and maximize the potential of Apremilast, reach out to us now by clicking on one of our BD members below.
paulo.rodriguez@adalvo.com – Europe
marta.puig@adalvo.com - South Europe
marc.nolasco@adalvo.com - West Europe
jose.rendueles@adalvo.com- North Europe, CEE & APAC
supreet.sharma@adalvo.com – North America & Canada
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
bruno.alves@adalvo.com - Brazil & MENA
ajish.rajan@adalvo.com – Brands & Specialty Products
arni.baldursson@adalvo.com - Head of Global BD&L
Click on your preferred Business Partner and get in touch today!